AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Linzess/Constella (linaclotide) by Quarter
Linzess/Constella (linaclotide) — U.S. net revenues ($M) ($M)
AbbVie Linzess/Constella (linaclotide): $283M in Q2 2026, up 14.6% from a year earlier.
Latest, Q2 2026
283
Period ended Jun 30, 2026
Change on a year earlier
+14.6%
247 in Q2 2025
History
29 quarters
Since Q2 2019
Sources
24
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-03) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Linzess/Constella (linaclotide) ($M), quarterly Q2 2019–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/linzess-us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.